HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology6 papers

Secondary hyperaldosteronism

Last edited: 4/23/2026

Overview

Secondary hyperaldosteronism occurs due to factors other than primary adrenal disorders, leading to excessive aldosterone production and activity, often resulting in hypertension and hypokalemia. It manifests in various clinical scenarios including renal parenchymal disease, renovascular hypertension, and certain iatrogenic conditions, with varying degrees of benefit and harm depending on the underlying pathology 1.

Diagnosis

  • Clinical Presentation: Hypertension, hypokalemia, and metabolic alkalosis 1.
  • Laboratory Tests: Elevated plasma aldosterone concentration (PAC) to plasma renin activity (PRA) ratio, low serum potassium levels 1.
  • Renal Function Assessment: Evaluate creatinine clearance and electrolyte balance 1.
  • Imaging: Consider renal ultrasound or angiography to identify potential causes like renal artery stenosis 1.

    • Management

  • First-Line Treatments:
    • - Spironolactone or Eplerenone: Potassium-sparing diuretics to counteract hypokalemia and block aldosterone effects 1. - Angiotensin-Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers (ARBs): To reduce aldosterone secretion and improve blood pressure control 1.
  • Adjunctive Treatments:
    • - Address Underlying Cause: Specific interventions based on identified etiology (e.g., revascularization for renal artery stenosis) 1. - Potassium Supplementation: Monitor and correct hypokalemia carefully 1.

    Special Populations

  • Pregnancy: Aldosterone effects are more beneficial for volume conservation, with K-sparing mechanisms overriding hypokalemia risk 1.
  • Chronic Renal Failure: Hyperaldosteronism may offer some benefit but is limited by extrarenal targets of aldosterone action 1.

    • Key Recommendations

  • Target Underlying Cause: Prioritize treatment of the primary condition driving secondary hyperaldosteronism (e.g., renal artery stenosis, chronic kidney disease) to improve outcomes 1 (Evidence: Strong).
  • Use Aldosterone Antagonists: Initiate spironolactone or eplerenone to manage hypokalemia and hypertension 1 (Evidence: Moderate).
  • Incorporate RAS Inhibition: Employ ACE inhibitors or ARBs to reduce aldosterone secretion and enhance blood pressure control 1 (Evidence: Strong).

    • References

    1 Corry DB, Tuck ML. Secondary aldosteronism. Endocrinology and metabolism clinics of North America 1995. link

    Original source

    1. [1]
      Secondary aldosteronism. — Corry DB, Tuck ML Endocrinology and metabolism clinics of North America (1995)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG